“Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Metastatic Cutaneous Squamous Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S79, https://doi.org/10.25251/skin.2.supp.79.